Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Diane L. Rossi
Synthetic Lethality Exploitation by an Anti–Trop-2-Sn-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –Wild-Type Triple-Negative Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Evaluation of a Novel Hexavalent Humanized Anti-Igf-1r Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines
PLoS ONE
Multidisciplinary
Related publications
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-Sn-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Cancer
Cancer Research
Oncology
BRCA1/2-negative Hereditary Triple-Negative Breast Cancers Exhibit BRCAness
International Journal of Cancer
Cancer Research
Oncology
Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
PLoS ONE
Multidisciplinary
BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions
British Journal of Cancer
Cancer Research
Oncology
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize With PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
The Prevalence of BRCA1/2 Mutations of Triple-Negative Breast Cancer Patients in Xinjiang Multiple Ethnic Region of China
European Journal of Medical Research
Medicine
Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)
Biomedical Reports
Genetics
Pharmacology
Molecular Biology
Biochemistry
Neuroscience
Medicine
Toxicology
Pharmaceutics
Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
PLoS ONE
Multidisciplinary
